Novartis Loses Legal Battle Over its Flagship Heart Drug

Novartis loses legal battle over Entresto. The Swiss-based pharmaceutical and biotech company has failed to persuade a federal court to stop generic drugmaker MSN Pharmaceuticals from launching its own version of the heart failure drug, Reuters reported.

Specifically, a US court judge ruled that Novartis did not have sufficient grounds to justify suspending the launch of MSN. However, the court ordered the generic manufacturer to temporarily halt its production until Novartis can appeal the ruling.

Entresto is the most important drug in Novartis’ business, with sales of more than $6 billion last year. In 2022, the Swiss group began a fight against all manufacturers seeking to launch generic versions of the drug for infringing a patent that expires in 2026.

Novartis increases Entresto revenue by 30% in the first half of the year

Last July, the U.S. Food and Drug Administration approved MSN’s version of Entresto, making it the first generic drug in the United States. At the time, Novartis said it was “considering all available options to defend its intellectual property.”

Now, the judge also added that Novartis’ argument would cause “irreparable harm” by triggering a wave of Entresto generic launches by other drugmakers.

Novartis closed the first half of the year with a 9% growth, reaching 24.341 billion dollars. In the period between January and June, the group earned 5.934 billion dollars, 34% more than in the same period of the previous year. Entresto’s sales, meanwhile, stood at 3.777 billion dollars, 30% more than in the first half of 2023.

__

(Featured image by Marek Studzinski via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us